二甲双胍预防妊娠期糖尿病或肥胖孕妇妊娠期高血压疾病:随机试验的系统综述与Meta分析
该系统综述与Meta分析检索MEDLINE、Scopus和Cochrane Library至2017年9月,纳入15项随机对照试验,评估二甲双胍与妊娠期高血压疾病发生率的关系。在妊娠期糖尿病孕妇中,与胰岛素相比,二甲双胍与妊娠期高血压风险降低相关(RR 0.56,95%CI 0.37-0.85;I²=0%;1260名女性),子痫前期风险非显著降低(RR 0.83,95%CI 0.60-1.14;I²=0%;1724名女性)。作者结论认为二甲双胍使用与其他治疗或安慰剂相比很可能与妊娠期高血压疾病发生率降低相关,但纳入研究数量少、证据质量低和临床异质性限制结果外推,亟需进一步前瞻性试验。
要点
- 妊娠期糖尿病孕妇中,与胰岛素相比,二甲双胍与妊娠期高血压风险降低相关(RR 0.56,95%CI 0.37-0.85)。
- 妊娠期糖尿病孕妇中,与胰岛素相比,二甲双胍与子痫前期风险非显著降低相关(RR 0.83,95%CI 0.60-1.14)。
- 肥胖孕妇中,与安慰剂相比,二甲双胍与子痫前期风险非显著降低相关(RR 0.74,95%CI 0.09-6.28;I²=86%)。
核心结论
- 与其他治疗或安慰剂相比,二甲双胍使用很可能与妊娠期高血压疾病发生率降低相关,但纳入研究数量少、证据质量低和临床异质性限制结果推广至更广泛人群,亟需进一步前瞻性试验。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE(1947年至2017年9月)、Scopus(1970年至2017年9月)和Cochrane Library(创刊至2017年9月)的英文文献。
- 仅纳入报告子痫前期或妊娠期高血压发生率的二甲双胍随机对照试验,排除随机化前极可能使用二甲双胍的人群(II型糖尿病或多囊卵巢综合征)。
- 共3337条引用符合检索标准,评估2536篇摘要并全文审查52项研究后,15项纳入综述。
主要发现
- 妊娠期糖尿病孕妇中,与胰岛素相比,二甲双胍与妊娠期高血压风险降低相关(RR 0.56;95%CI 0.37-0.85;I²=0%;1260名女性)。
- 妊娠期糖尿病孕妇中,与胰岛素相比,二甲双胍与子痫前期风险非显著降低相关(RR 0.83;95%CI 0.60-1.14;I²=0%;1724名女性)。
- 肥胖孕妇中,与安慰剂相比,二甲双胍与子痫前期风险非显著降低相关(RR 0.74;95%CI 0.09-6.28;I²=86%;840名女性)。
- 妊娠期糖尿病孕妇中,与格列本脲相比,二甲双胍与任何妊娠期高血压疾病风险非显著降低相关(RR 0.71;95%CI 0.41-1.25;I²=0%;556名女性)。
- 以治疗类型为协变量的贝叶斯随机效应Meta回归显示,与其他任何治疗或安慰剂相比,二甲双胍对预防子痫前期、妊娠期高血压和任何妊娠期高血压疾病有益的后验概率分别为92.7%、92.8%和99.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纳入分析的研究数量少。
- 证据质量低。
- 临床异质性妨碍将这些结果推广至更广泛人群。
- 鉴于该主题的临床重要性和本Meta分析观察到的效应量,亟需进一步前瞻性试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Metformin has been reported to reduce the risk of pre-eclampsia. It is also known to influence soluble fms-like tyrosine kinase-1 level, which correlates significantly with the gestational age at onset and severity of pre-eclampsia. The main aim of this systematic review and meta-analysis of randomized trials was to determine whether metformin use is associated with the incidence of hypertensive disorders of pregnancy (HDP). METHODS: MEDLINE (1947 to September 2017), Scopus (1970 to September 2017) and the Cochrane Library (inception to September 2017) were searched for relevant citations in the English language. Only randomized controlled trials on metformin use, reporting the incidence of pre-eclampsia or pregnancy-induced hypertension, were included. Studies on populations with a high probability of metformin use prior to randomization (those with type II diabetes or polycystic ovary syndrome) were excluded. Random-effects models with the Mantel-Haenszel method were used for subgroup analyses. Bayesian random-effects meta-regression was used to summarize the evidence. RESULTS: In total, 3337 citations matched the search criteria. After evaluating 2536 abstracts and performing full-text review of 52 studies, 15 were included in the review. In women with gestational diabetes, metformin use was associated with a reduced risk of pregnancy-induced hypertension when compared with insulin (relative risk (RR), 0.56; 95% CI, 0.37-0.85; I2 = 0%; 1260 women) and a non-significantly reduced risk of pre-eclampsia (RR, 0.83; 95% CI, 0.60-1.14; I2 = 0%; 1724 women). In obese women, when compared with placebo, metformin use was associated with a non-significant reduction in risk of pre-eclampsia (RR, 0.74; 95% CI, 0.09-6.28; I2 = 86%; 840 women). In women with gestational diabetes, metformin use was also associated with a non-significant reduction in risk of any HDP (RR, 0.71; 95% CI, 0.41-1.25; I2 = 0%; 556 women) when compared with glyburide. When studies were combined using Bayesian random-effects meta-regression, with treatment type as a covariate, the posterior probabilities of metformin having a beneficial effect on the prevention of pre-eclampsia, pregnancy-induced hypertension and any HDP were 92.7%, 92.8% and 99.2%, respectively, when compared with any other treatment or placebo. CONCLUSIONS: There is a high probability that metformin use is associated with reduced HDP incidence when compared with other treatments or placebo. The small number of studies included in the analysis, the low quality of evidence and the clinical heterogeneity preclude generalization of these results to broader populations. Given the clinical importance of this topic and the magnitude of effect observed in this meta-analysis, further prospective trials are urgently needed. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Kalafat E, Sukur YE, Abdi A, et al. Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. Ultrasound Obstet Gynecol. 2018. PMID: 29749110. doi:10.1002/uog.19084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。